News

  • Mar 3, 2016

    Circadin® 2mg (prolonged-release melatonin) is now commercially available in Peru

  • Mar 2, 2016

    Circadin® 2mg (prolonged-release melatonin) is now commercially available in Argentina

  • Jan 11, 2016

    Circadin® 2mg (prolonged-release melatonin) is now commercially available in South Africa

  • Oct 1, 2015

    Circadin® 2mg (prolonged-release melatonin) is now commercially available in Colombia

  • Sep 18, 2015

    Circadin® receives marketing authorization in Peru

  • Mar 2, 2015

    Vigisom® 2mg (prolonged-release melatonin) is now commercially available in Chile

  • Sep 7, 2014

    Circadin® receives marketing authorization in South Africa

  • Sep 1, 2014

    Circadin® receives marketing authorization in South Korea

  • Aug 27, 2014

    Neurim Pharmaceuticals initiates Phase III study of Paediatric Prolonged-Release Melatonin in children with Autistic Spectrum Disorders, suffering from sleep disturbances

  • Jun 19, 2014

    Neurim Pharmaceuticals Announces Publication of Positive Effects of Add-on Circadin® in Alzheimer’s Disease Patients (Read more)

  • Feb 18, 2013

    Neurim Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of Piromelatine for the Treatment of Insomnia (Read more)

  • Feb 22, 2012

    Neurim Pharmaceuticals reports the results of stabilometric study of Circadin® demonstrating maintenance of postural stability (Read more)

  • Jul 24, 2011

    Neurim Pharmaceuticals announces positive results from phase I and Ib clinical trials with Neu-P11, a sleep maintenance drug (Read more)

  • Jul 24, 2011

    Neurim Pharmaceuticals reports the results of stabilometric study of Circadin® demonstrating maintenance of postural stability (Read more)

  • Jun 22, 2011

    Neurim Pharmaceuticals is currently performing a clinical trial in Korea to obtain Circadin® marketing authorization

  • Jun 16, 2011

    Circadin® receives marketing authorization in New Zealand

  • May 17, 2011

    Circadin® use approved for up to 3 months in Switzerland

  • Apr 4, 2011

    Circadin® use approved for up to 3 months in Hong Kong

  • Jan 4, 2011

    TGA approves Circadin® use for up to 3 months

  • Oct 4, 2010

    Circadin® use approved for up to 3 months in Macedonia

  • Text size: A A A
  • Circadin
  • Recent news

    • Slenyto® (PedPRM) was approved by EMA for the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient
    • NEURIM PHARMACEUTICALS RECEIVES POSITIVE CHMP OPINION FOR SLENYTO® (PEDIATRIC PROLONGED-RELEASE MELATONIN) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH AUTISM SPECTRUM DISORDER (ASD)
    • Neurim Pharmaceuticals attends the INSAR Congress in Rotterdam, The Netherlands, May 9-11, 2018
  • Partners

    Partners